Viatris (VTRS)
(Delayed Data from NSDQ)
$11.35 USD
-0.21 (-1.82%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $11.34 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
Company Summary
Viatris, a global healthcare company, was formed in November 2020 through the merger of the erstwhile Mylan and Pfizer’s Upjohn businesses. The company’s portfolio consists of more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic and complex generic products. Branded products include EpiPen, Amitiza, Lipitor and Viagra.
The company reports its business in segments based on markets and geography. The segments are Developed Markets, Greater China, JANZ and Emerging Markets. The Developed Markets segment comprises operations primarily in North America ...
Company Summary
Viatris, a global healthcare company, was formed in November 2020 through the merger of the erstwhile Mylan and Pfizer’s Upjohn businesses. The company’s portfolio consists of more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic and complex generic products. Branded products include EpiPen, Amitiza, Lipitor and Viagra.
The company reports its business in segments based on markets and geography. The segments are Developed Markets, Greater China, JANZ and Emerging Markets. The Developed Markets segment comprises operations primarily in North America and Europe. The Greater China segment includes operations in China, Taiwan and Hong Kong. While the JANZ segment reports on operations in Japan, Australia and New Zealand, the Emerging Markets segment will include operations in countries with developing markets and emerging economies, including nations in Asia, the Middle East, South and Central America, Africa and Eastern Europe.
The company intends to focus on three core therapeutic areas — ophthalmology, dermatology and gastrointestinal.
In November 2022, Viatris completed the sale of its biosimilars portfolio to Biocon Biologics. Per the terms, Viatris received $3 billion in consideration in the form of a $2 billion cash payment and approximately $1 billion of compulsory convertible preferred shares representing a stake of approximately 12.9% in Biocon Biologics. Viatris is entitled to $335 million of additional cash payments in 2024.
During the first quarter of 2023, Viatris acquired ophthalmic disease-focused company Oyster Point for approximately $427.4 million in cash. In November 2022, Viatris entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for $281 million. The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023.
Total revenues came in at $15.4 billion in 2023, down 5% year over year.
General Information
Viatris Inc
1000 MYLAN BOULEVARD
CANONSBURG, PA 15317
Phone: 724-514-1800
Fax: 724-514-1870
Web: http://www.viatris.com/en
Email: investorrelations@viatris.com
Industry | Medical Services |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 8/8/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.68 |
Current Year EPS Consensus Estimate | 2.72 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 8/8/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 11.56 |
52 Week High | 13.62 |
52 Week Low | 8.74 |
Beta | 0.94 |
20 Day Moving Average | 7,416,701.50 |
Target Price Consensus | 12.83 |
4 Week | 8.95 |
12 Week | 1.76 |
YTD | 6.74 |
4 Week | 17.07 |
12 Week | 2.45 |
YTD | -1.83 |
Shares Outstanding (millions) | 1,190.68 |
Market Capitalization (millions) | 13,764.21 |
Short Ratio | NA |
Last Split Date | 10/9/2003 |
Dividend Yield | 4.15% |
Annual Dividend | $0.48 |
Payout Ratio | 0.17 |
Change in Payout Ratio | 0.09 |
Last Dividend Payout / Amount | 5/23/2024 / $0.12 |
Fundamental Ratios
P/E (F1) | 4.26 |
Trailing 12 Months | 4.11 |
PEG Ratio | NA |
vs. Previous Year | -14.10% |
vs. Previous Quarter | 9.84% |
vs. Previous Year | -1.76% |
vs. Previous Quarter | -4.53% |
Price/Book | 0.69 |
Price/Cash Flow | 2.21 |
Price / Sales | 0.90 |
6/30/24 | NA |
3/31/24 | 16.63 |
12/31/23 | 17.03 |
6/30/24 | NA |
3/31/24 | 7.10 |
12/31/23 | 7.28 |
6/30/24 | NA |
3/31/24 | 1.67 |
12/31/23 | 1.67 |
6/30/24 | NA |
3/31/24 | 1.17 |
12/31/23 | 1.22 |
6/30/24 | NA |
3/31/24 | 22.25 |
12/31/23 | 22.93 |
6/30/24 | NA |
3/31/24 | -0.37 |
12/31/23 | 0.35 |
6/30/24 | NA |
3/31/24 | 0.55 |
12/31/23 | 1.32 |
6/30/24 | NA |
3/31/24 | 16.81 |
12/31/23 | 17.06 |
6/30/24 | NA |
3/31/24 | 2.45 |
12/31/23 | 2.49 |
6/30/24 | NA |
3/31/24 | 0.80 |
12/31/23 | 0.79 |
6/30/24 | NA |
3/31/24 | 44.54 |
12/31/23 | 44.16 |